Royal Society of Chemistry, RSC Advances, 21(10), p. 12384-12394, 2020
DOI: 10.1039/d0ra00287a
Full text: Download
LASSBio-1736 was identified as a new antileishmanial drug-candidate bearing an original framework and displaying plasma stability, cytotoxicity against amastigote forms of Leishmania species and leishmanicidal activity in a cutaneous leishmaniasis murine model.